Immunosuppressed

免疫抑制
  • 文章类型: Case Reports
    鼻咽癌(NPC)合并非结核分枝杆菌肺病(NTM-PD)的患者在临床上非常罕见,我们的病例是首例NPC合并NTM-PD的患者。对于肿瘤学家来说,快速控制感染症状对于治疗原发性疾病至关重要。
    一名58岁男性,在鼻咽癌化疗后出现NTM-PD。化疗后粒细胞缺乏症是各种感染性疾病发展的主要因素。患者头部MRI发现鼻咽肿瘤,鼻咽部恶性肿瘤经内镜切除鼻内病变后病理检查,然后在肿瘤科证实鼻咽部非角化性癌(T4N1M0,IV期)。患者化疗后出现骨髓抑制,因感染性休克入院。胸部CT检查提示肺部感染,经验性抗生素治疗无效。NGS结果显示患者感染了分枝杆菌脓肿。我们用头孢西丁和莫西沙星治疗可显着减少肺部病变。
    带有NTM-PD的NPC非常罕见,NTM-PD的治疗对患者原发疾病的预后非常重要。我们的研究为免疫抑制患者的抗感染治疗提供了经验。
    UNASSIGNED: Patients with nasopharyngeal carcinoma (NPC) combined with non-tuberculous Mycobacteria-pulmonary disease (NTM-PD) are very rare in the clinic, and our case is the first patient with NPC combined with NTM-PD. For oncologists, rapid control of the symptoms of infection is essential to the treatment of the primary disease.
    UNASSIGNED: A 58-year-old man who developed a NTM-PD after chemotherapy for nasopharyngeal carcinoma. Granulocytosis after chemotherapy is a major factor in the development of various infectious diseases. Nasopharyngeal tumor was found on MRI of the patient\'s head, and nasopharyngeal malignant tumor was considered after pathological examination after endoscopic resection of intranasal lesion, and then nasopharyngeal non-keratonic carcinoma (T4N1M0, stage IV) was confirmed in the department of oncology. The patient developed bone marrow suppression after chemotherapy and was admitted to hospital due to septic shock. Chest CT examination indicated pulmonary infection, and empirical antibiotic treatment was not effective. The NGS results showed that the patient was infected with Mycobacterium abscess. We treated with cefoxitin followed by moxifloxacin to reduce the lung lesions significantly.
    UNASSIGNED: NPC with NTM-PD is very rare, and the treatment of NTM-PD is very important for the prognosis of the patient\'s primary disease. Our study provides experience for anti-infection treatment of patients with immunosuppression.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    白天鹅膏,一个小孢子虫,已经成为一种机会病原体,特别是患有类风湿关节炎等免疫功能低下的个体,器官移植,和恶性血液病.令人惊讶的是,尽管它有公认的影响,尚未记录在腹水中鉴定A。因此,我们指出,在有急性髓细胞性白血病病史和长期免疫抑制治疗的患者中,Algerae可能是腹水蓄积的诱因。对这个病人来说,没有甲藻相关感染的迹象(例如,肌炎),声带受累,或播散性感染。通过对腹水的下一代宏基因组测序分析,最终确定了Aalgerae的存在。临床表现以C反应蛋白水平升高(110.7mg/L)为特征,血小板计数减少(48×109/L),腹胀继发腹水积聚,下肢疼痛,在磺胺甲恶唑/甲氧苄啶和阿苯达唑4天的治疗方案后,它显示出明显的改善。尽管有这种有希望的反应,病人因呕吐物误吸而死亡。这个案例强调了考虑更稀有生物的重要性,如藻类感染,免疫功能低下并存在无法解释的腹水积聚的患者。它强调了磺胺甲恶唑/甲氧苄啶和阿苯达唑在处理此类病例中的潜在有效性。进一步的研究是必要的,以阐明最佳的管理策略和改善结果在类似的临床情况。
    Anncaliia algerae, a microsporidium, has risen to prominence as an opportunistic pathogen, particularly afflicting individuals who are immunocompromised with conditions such as rheumatoid arthritis, organ transplantation, and hematologic malignancy. Surprisingly, despite its recognized impact, the identification of A algerae in ascitic fluid has not been documented. As such, we pinpointed A algerae as the probable instigator of ascitic accumulation in a patient with a history of acute myeloid leukemia and extended periods of immunosuppressive therapy. For this patient, there were no signs of A algerae-related infections (eg, myositis), vocal cord involvement, or disseminated infection. The presence of A algerae was finally identified by next-generation metagenomic sequencing analysis of the ascitic fluid. Clinical presentation was characterized by elevated C-reactive protein levels (110.7 mg/L), diminished platelet count (48 × 109/L), abdominal distension secondary to ascitic fluid accumulation, and lower limb pain, and it showed marked improvement following a 4-day regimen of sulfamethoxazole/trimethoprim and albendazole. Despite this promising response, the patient succumbed to aspiration of vomitus. This case underscores the importance of considering rarer organisms, such as A algerae infection, in patients who are immunocompromised and present with unexplained ascites accumulation. It highlights the potential effectiveness of sulfamethoxazole/trimethoprim and albendazole in managing such cases. Further research is warranted to elucidate optimal management strategies and improve outcomes in similar clinical scenarios.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    评估2023年11种呼吸道病原体的阳性率,对COVID-19大流行后的呼吸道感染模式进行全面总结和分析。该研究包括从2022年7月至2023年12月31日接受呼吸道病原体多重聚合酶链反应测试的7544名疑似呼吸道感染的住院患者。我们分析了18个月内11种病原体的阳性率以及不同年龄组和免疫状态之间的感染模式特征。在7544名患者中(年龄范围为4个月至104岁,44.99%女性),11种病原体中至少一种感染的发生率为26.07%。儿童(55.18%,p<0.05)的感染概率明显高于成年人(20.88%)和老年人(20.66%)。甲型流感病毒(8.63%),肺炎支原体(5.47%),最常见的病原体是人鼻病毒(5.12%)。在儿童中,肺炎支原体(35.96%)取代了人呼吸道合胞病毒(HRSV)(5.91%)在病原体谱中的主要作用。年龄,免疫抑制状态,和呼吸道慢性疾病与混合感染的风险显著升高相关。免疫抑制患者更容易感染人类冠状病毒(4.64%vs.1.65%,p<0.05),人类副流感病毒(3.46%vs.1.69%,p<0.05),和HRSV(2.27%vs.0.55%,p<0.05)。随着地区流行病控制措施和COVID-19大流行,呼吸道感染的模式发生了变化。
    To assess the positive rate of 11 respiratory pathogens in 2023, providing a comprehensive summary and analysis of the respiratory infection patterns after COVID-19 pandemic. The study comprised 7544 inpatients suspected of respiratory infections who underwent respiratory pathogen multiplex polymerase chain reaction tests from July 2022 to December 31, 2023. We analyzed the positive rate of 11 pathogens over 18 months and the characterization of infection patterns among different age groups and immune states. Among 7544 patients (age range 4 months to 104 years, 44.99% female), the incidence of infected by at least one of the 11 pathogens was 26.07%. Children (55.18%, p < 0.05) experienced a significantly higher infection probability than adults (20.88%) and old (20.66%). Influenza A virus (8.63%), Mycoplasma pneumoniae (5.47%), and human rhinovirus (5.12%) were the most common pathogens. In children, M. pneumoniae (35.96%) replaced the predominant role of human respiratory syncytial virus (HRSV) (5.91%) in the pathogen spectrum. Age, immunosuppressed state, and respiratory chronic conditions were associated with a significantly higher risk of mixed infection. Immunosuppressed patients were more vulnerable to human coronavirus (4.64% vs. 1.65%, p < 0.05), human parainfluenza virus (3.46% vs. 1.69%, p < 0.05), and HRSV (2.27% vs. 0.55%, p < 0.05). Patterns in respiratory infections changed following regional epidemic control measures and the COVID-19 pandemic.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:免疫抑制对碳青霉烯类耐药菌(CRO)血流感染(BSI)预后的影响尚不清楚。这项研究的目的是阐明免疫抑制与CRO-BSI死亡率之间的关系,并确定与免疫抑制患者死亡率相关的危险因素。
    方法:这项回顾性研究包括2018年1月至2023年3月的279例CRO-BSI患者。比较免疫抑制和免疫功能正常患者的临床特征和结果。通过logistic回归分析评估免疫抑制与BSI发病后30天死亡率之间的关系。倾向评分匹配(PSM)和治疗加权逆概率(IPTW)。采用多变量logistic回归分析与免疫抑制患者死亡率相关的因素。
    结果:共纳入88名免疫功能正常和191名免疫抑制患者,30天全因死亡率为58.8%。尽管免疫抑制患者的30天死亡率显着高于免疫功能正常患者(46.6%vs.64.4%,P=0.007),在多因素logistic回归分析中,免疫抑制不是死亡的独立危险因素(比值比[OR]3.53,95%置信区间[CI]0.74-18.89;P=0.123),PSM(OR1.38,95%CI0.60-3.18;P=0.449,)或IPTW(OR1.40,95%CI0.58-3.36;P=0.447)。对于CRO-BSI患者,不管免疫状态如何,适当的抗生素治疗与30天死亡率降低相关,而Charlson合并症指数(CCI),CRO-BSI发病时重症监护病房(ICU)获得性感染和血小板减少与死亡率增加相关.
    结论:尽管CRO-BSI的死亡率很高,免疫抑制并不影响死亡率.适当的抗生素治疗对于改善CRO-BSI的预后至关重要。无论免疫状态如何。
    BACKGROUND: The impact of immunosuppression on prognosis of carbapenem-resistant organism (CRO) bloodstream infection (BSI) remains unclear. The aim of this study was to clarify the relationship between immunosuppression and mortality of CRO-BSI and to identify the risk factors associated with mortality in immunosuppressed patients.
    METHODS: This retrospective study included 279 patients with CRO-BSI from January 2018 to March 2023. Clinical characteristics and outcomes were compared between the immunosuppressed and immunocompetent patients. The relationship between immunosuppression and 30-day mortality after BSI onset was assessed through logistic-regression analysis, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). Factors associated with mortality in immunosuppressed patients were analyzed using multivariable logistic regression analysis.
    RESULTS: A total of 88 immunocompetent and 191 immunosuppressed patients were included, with 30-day all-cause mortality of 58.8%. Although the 30-day mortality in immunosuppressed patients was significantly higher than in immunocompetent patients (46.6% vs. 64.4%, P = 0.007), immunosuppression was not an independent risk factor for mortality in multivariate logistic regression analysis (odds ratio [OR] 3.53, 95% confidence interval [CI] 0.74-18.89; P = 0.123), PSM (OR 1.38, 95% CI 0.60-3.18; P = 0.449,) or IPTW (OR 1.40, 95% CI 0.58-3.36; P = 0.447). For patients with CRO-BSI, regardless of immune status, appropriate antibiotic therapy was associated with decreased 30-day mortality, while Charlson comorbidity index (CCI), intensive care unit (ICU)-acquired infection and thrombocytopenia at CRO-BSI onset were associated with increased mortality.
    CONCLUSIONS: Despite the high mortality rate of CRO-BSI, immunosuppression did not affect the mortality. Appropriate antibiotic therapy is crucial for improving the prognosis of CRO-BSI, regardless of the immune status.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    植物源性多糖,如苍术根茎多糖(ALP),是很好的免疫调节剂。然而,ALP的免疫调节机制尚不清楚。本研究旨在评价ALP对免疫抑制小鼠肠黏膜屏障及肠黏膜免疫功能的影响。我们还比较了生苍术根茎多糖(SALP)与麦麸加工的麸皮油炸苍术根茎多糖(FALP;小鼠均为1.2g/kg/d)的活性。我们的结果表明,ALP有效地增加了免疫器官指数和血细胞计数,刺激细胞因子的分泌,并促进了闭塞蛋白和闭塞带1(ZO-1)的表达。ALP还促进T细胞的表达和sIgA的分泌。此外,ALP缓解了Cy处理的小鼠的肠道微生物群紊乱,并增加了乳杆菌和粪杆菌的相对丰度。ALP逆转了SCFAs水平的降低,并促进了G蛋白偶联受体43(GPR43)的表达。据我们所知,本研究首次探讨ALP如何通过减轻SCFAs的肠道菌群失衡和代谢紊乱来保护肠黏膜屏障和增强肠黏膜免疫。FALP比SALP更具治疗性,这表明FALP可以被开发为一种有前途的功能性食品成分。
    Plant-derived polysaccharides, such as Atractylodes lancea rhizome polysaccharide (ALP), are good immune regulators. However, the immune regulatory mechanism of the ALP is unknown. This study aimed to evaluate the effects of ALP on the intestinal mucosal barrier and intestinal mucosal immunity of immunosuppressed mice. We also compared the activity of raw Atractylodes lancea rhizome polysaccharide (SALP) with wheat bran processed bran-fried Atractylodes lancea rhizome polysaccharide (FALP; both at 1.2 g/kg/d for mice). Our results showed that ALP effectively increased the immune organ index and blood cell count, stimulated the secretion of cytokines, and promoted the expression of occludin and zonula occludens-1 (ZO-1). ALP also promoted the expression of T cells and the secretion of sIgA. Furthermore, ALP alleviated the gut microbiota disorder in Cy-treated mice and increased the relative abundances of Lactobacillus and Faecalibaculum. ALP reversed the decrease in the level of SCFAs and promoted the expression of G protein-coupled receptor 43 (GPR43). To our knowledge, this study was the first to explore how the ALP protects the intestinal mucosal barrier and enhances intestinal mucosal immunity by alleviating the gut microbiota imbalance and metabolic disorders of SCFAs. FALP was more therapeutic than SALP, suggesting that FALP could be developed as a promising functional food component.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:探讨改良护理策略对免疫抑制肺炎合并脓毒症患者预后的影响。方法:选择免疫功能低下(淋巴细胞绝对计数<1000细胞/mm3)的肺炎和脓毒症患者,分为对照组和治疗组。治疗组接受改进的护理策略。这项研究的主要结果是28天死亡率。结果:根据研究标准,最终纳入1019例患者。与对照组患者相比,治疗组的机械通气天数明显减少[5(4,7)与5(4,7)天,P=.03]和更低的重症监护病房(ICU)死亡率[21.1%(627中的132)对28.8%(392中的113);P=.005]和28天死亡率[22.2%(627中的139)对29.8%(392中的117);P=.006]。治疗组的ICU住院时间也较短[9(5,15)vs11(6,22)天,P=.0001]比对照组。改进的护理策略是28天死亡率的独立保护因素:比值比0.645,95%置信区间:0.449-0.927,P=0.018。结论:我们改进的护理策略缩短了机械通气时间和ICU住院时间,降低了肺炎和脓毒症免疫抑制患者的ICU死亡率和28天死亡率。试用注册:ChiCTR.org。cn,ChiCTR-ROC-17010750。2017年2月28日注册
    Objectives: To investigate the effect of our improved nursing strategy on prognosis in immunosuppressed patients with pneumonia and sepsis. Methods: Immunosuppressed patients (absolute lymphocyte count <1000 cells/mm3) with pneumonia and sepsis were enrolled and divided into a control group and treatment group. The treatment group received the improved nursing strategy. The primary outcome in this study was 28-day mortality. Results: In accordance with the study criteria, 1019 patients were finally enrolled. Compared with patients in the control group, those in the treatment group had significantly fewer days on mechanical ventilation [5 (4, 7) versus 5 (4, 7) days, P = .03] and lower intensive care unit (ICU) mortality [21.1% (132 of 627) vs 28.8% (113 of 392); P = .005] and 28-day mortality [22.2% (139 of 627) vs 29.8% (117 of 392); P = .006]. The treatment group also had a shorter duration of ICU stay [9 (5, 15) vs 11 (6, 22) days, P = .0001] than the control group. The improved nursing strategy acted as an independent protective factor in 28-day mortality: odds ratio 0.645, 95% confidence interval: 0.449-0.927, P = .018. Conclusion: Our improved nursing strategy shortened the duration of mechanical ventilation and the ICU stay and decreased ICU mortality and 28-day mortality in immunosuppressed patients with pneumonia and sepsis. Trial registration: ChiCTR.org.cn, ChiCTR-ROC-17010750. Registered 28 February 2017.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Published Erratum
    [这更正了文章DOI:10.3389/fmed.202.996442。].
    [This corrects the article DOI: 10.3389/fmed.2022.996442.].
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:本研究旨在评估服用免疫抑制剂的患者用水凝胶结合抗微生物蛋白酶敷料和情绪支持干预治疗的慢性伤口的愈合过程。
    方法:病例系列涉及8名在三级公立医院治疗12周的患者。数据采用SPSS27.0版进行分析。实施了意向治疗原则,不损失或排除参与者。受试者有70(98)天的伤口,男性占50%(4/8),平均年龄42.63岁(±16.94)。所有(100%)受试者都服用了免疫抑制剂,收缩期高血压占62.5%(5/8)。所有伤口的平均初始面积为19.54(5.89)cm2,平均最终面积为3.0cm2,在12周的治疗中减少率为89%。此外,我们发现这些伤口的组织类型通过使用水凝胶结合抗菌蛋白酶敷料而改变,尤其是失活组织(P=0.011)。渗出物的量没有统计学变化(P=0.083)。在研究期间,没有参与者出现严重或局部不良事件。因此,给予情感支持以及12周的伤口护理可显著降低焦虑评分(P=0.012).这些结果表明,水凝胶与抗微生物蛋白酶敷料和情绪支持干预相结合是一种有希望的方法,用于治愈患有免疫抑制疾病或正在接受当前免疫抑制治疗的患者的伤口。
    BACKGROUND: This study aimed to evaluate the healing process of chronic wounds treated with hydrogel combined with antimicrobial protease dressing and emotional support intervention in patients taking immunosuppressive agents.
    METHODS: The case series involved 8 patients treated at a tertiary public hospital for 12 weeks. Data were analysed by SPSS version 27.0. The intention-to-treat principle was carried out, without the loss or exclusion of the participants. The subjects had wounds for 70 (98) days, and they consisted of 50% (4/8) males with a mean age of 42.63 years (±16.94). All (100%) subjects had taken immunosuppressive agents, and 62.5% (5/8) had systolic hypertension. The mean initial area of all wounds was 19.54 (5.89) cm2, and the mean final area was 3.0 cm2, with a reduction rate of 89% over the 12 weeks of treatment. In addition, we found that tissue types of these wounds changed by using hydrogel combined with antibacterial protease dressings, especially devitalised tissue (P = 0.011). The amount of exudate did not statistically change (P = 0.083). No participant had severe or local adverse events during the study period. Hence, giving emotional support along with wound care for 12 weeks could significantly reduce anxiety scores (P = 0.012). These results suggested that hydrogel combined with antimicrobial protease dressing and emotional support intervention is a promising method for the healing of wounds in patients who suffer from immunosuppressive diseases or are receiving current immunosuppressive treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    未经评估:本研究的目的是描述和分析诺卡心病的临床特征。
    UNASSIGNED:我们从以下几个方面描述和分析了过去5年来自两个中心的诺卡病病例的临床特征:年龄和性别,诺卡氏菌物种,诺卡氏菌感染部位,试样,检测方法,并发病原体,症状,成像特征,共同条件,药敏试验,抗生素治疗/持续时间,结果,和后续行动。
    未经评估:19例患者的中位年龄为64岁,四分位数间距(IQR)为56-68年。8例(42.1%)免疫功能低下[那些使用皮质类固醇的人(62.5%),使用过免疫抑制剂的人(50.0%),或患有慢性肾病(37.5%)或糖尿病(DM)(25.0%)的人]。这些病例的过多合并症包括糖尿病(10.5%),慢性肾脏病(CDK)(15.8%),慢性肺病(36.8%),和风湿性疾病(10.5%)。咳嗽和咳痰(73.7%)是诺卡心症最常见的症状。呼吸道(89.5%)是临床疾病的最常见部位。近一半(9例,47.3%)的这些患者并发感染。最常见的诺卡氏菌隔离部位是呼吸道(73.7%)。所有患者均给予抗生素治疗,其中多达63.6%的患者同时使用两种抗菌药物治疗,15.8%的患者在单一疗法下治疗,21.1%的患者同时使用三种或更多种抗菌药物治疗。
    未经证实:一种罕见的危及生命的感染,心源性心脏病,影响那些患有结构性肺病或免疫抑制的患者。尽管诺卡病能够发展为严重的转移性疾病,早期识别和及时治疗通常会导致患者受益的成功结果.
    UNASSIGNED: The objective of the present study was to describe and analyze the clinical characteristics of nocardiosis.
    UNASSIGNED: We described and analyzed the clinical characteristics of nocardiosis cases from two centers over the past 5 years from the following aspects: age and sex, Nocardia species, sites of Nocardia infection, test specimens, detection methods, concurrent pathogens, symptoms, imaging features, co-conditions, drug susceptibility tests, antibiotic therapy/duration, outcomes, and follow-up.
    UNASSIGNED: The median age of the 19 cases was 64 years, with an interquartile range (IQR) of 56-68 years. Eight cases (42.1%) were immunocompromised [those who had been on corticosteroid use (62.5%), those who had used immunosuppressants (50.0%), or those who had suffered from chronic nephrosis (37.5%) or diabetes mellitus (DM) (25.0%)]. The plethora of comorbidities of these cases included diabetes (10.5%), chronic kidney disease (CDK) (15.8%), chronic lung disease (36.8%), and rheumatic diseases (10.5%). Cough and expectoration (73.7%) was the most common symptom of nocardiosis. The respiratory tract (89.5%) was the most common site of the clinical disease. Nearly half (9 cases, 47.3%) of these patients had concurrent infections. The most common Nocardia isolation site was the respiratory tract (73.7%). All patients were given antibiotic therapies, out of whom as many as 63.6% of patients were treated with two concurrent antimicrobial agents, 15.8% of patients were treated under monotherapy and 21.1% of patients were treated with three or more concurrent antimicrobial agents.
    UNASSIGNED: An uncommon life-threatening infection, nocardiosis, affects those patients with structural lung disease or immunosuppression. Although nocardiosis is capable of progressing into a serious and metastatic disease, early recognition and prompt treatment usually result in successful outcomes benefitting the patient.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    方法:免疫抑制是一系列疾病的主要危险因素之一,如肿瘤,类风湿性关节炎,和微生物感染。各种天然产物因其免疫调节活性而受到广泛关注。在这里,该研究调查了免疫抑制小鼠中Holothurialeucospilota多糖(HLP)的调节。
    结果:8周龄雌性BALB/c小鼠腹腔注射环磷酰胺(80mg/kg体重/d),建立免疫抑制模型。HLP治疗12天后,免疫器官指数,血清细胞因子,免疫球蛋白水平显著升高(P<0.05)。实时荧光定量聚合酶链反应和免疫印迹分析发现,HLP提高了免疫因子,T细胞标志物,和Toll样受体(TLR)通路相关蛋白表达。同时,HLP显著增加短链脂肪酸浓度,调节肠道菌群组成(P<0.05)。此外,宏基因组学分析表明,HLP增加了参与氨基酸代谢的功能基因的水平,碳水化合物代谢,和肠道微生物群的生长活动。
    结论:HLP干预可改善小鼠的免疫功能,有益作用与肠道稳态调节和TLR通路激活密切相关。这项研究表明HLP作为益生元在新型免疫增强剂开发中的潜力。本文受版权保护。保留所有权利。
    Immunosuppression is one of the major risk factors for a series of diseases, such as tumor, rheumatoid arthritis, and microbial infection. Various natural products have attracted wide attention due to their immunomodulatory activities. Herein, the study investigates the regulation of Holothuria leucospilota polysaccharides (HLP) in immunosuppressed mice.
    Eight-week-old female BALB/c mice are injected intraperitoneally with cyclophosphamide (80 mg kg-1 body weight day-1 ) to establish the immunosuppressive model. After 12 days of HLP treatment, the immune organ indexes, serum cytokines, and immunoglobulin levels are significantly increased in immunosuppressed mice (p < 0.05). Real-time fluorescent quantitative polymerase chain reaction and western blotting analysis find that HLP improves the immune factors, T-cell markers, and Toll-like receptors (TLR) pathway-related proteins expression. Simultaneously, HLP significantly increases the short-chain fatty acids concentration and regulates the gut microbiota composition (p < 0.05). Furthermore, the metagenomics analysis shows that HLP increases the levels of functional genes involved in amino acid metabolism, carbohydrate metabolism, and growth activity of the gut microbiota.
    HLP intervention improves the mice\'s immune function, and the beneficial effects are closely associated with intestinal homeostasis regulation and TLR pathway activation. This study suggests the potential for HLP as prebiotics in novel immunopotentiators development.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号